【摘要】 以糖原为原料合成偶联VB12基团的阳离子糖原衍生物(GD-VB12),将作为口服纳米药物的载体材料。FTIR和~1H NMR结果证实二乙烯三胺阳离子基团和VB12基团均与糖原分子发生偶联,它们的取代度分别为0.9%和0.6%。GD-VB12衍生物在水中能形成纳米粒,粒径约为200～300 nm。GD-VB12衍生物在模拟胃液和小肠液中稳定性较高,有利于携带口服药物安全地通过消化道。GD-VB12衍生物在1 h内能快速被糖原磷酸化酶a降解。因此,GD-VB12衍生物将有可能作为口服药物的纳米传输载体被小肠吸收而进入体循环后,在肝脏和肌肉定位释放药物。更多还原

【Abstract】 A cationic glycogen derivative conjugated with vitamin B12(VB12) residues(GD-VB12) was synthesized and characterized using FTIR and ~1H NMR spectroscopy, which could be used as a nano-carrier for oral delivery of drugs. The degree of distribution of diethylenetriamine and VB12 residues were determined to be 0.9% and 0.6% using ~1H NMR integral method and UV-vis spectroscopy, respectively. The GD-VB12 derivative was observed as particles with irregular shape in the sizes ranging from 200 to 300 nm. It exhibited a high stability in the simulated gastric medium and the simulated small intestinal medium, and is beneficial for safe delivery of drugs through the digestive tract. The GD-VB12 derivative could be rapidly degraded by glycogen phosphorylase a within 1 h. Therefore, the GD-VB12 derivative possesses potential as a carrier for oral delivery of drugs safely and targeted release of drugs in the liver and muscle.更多还原